⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015386 | 0.80 | — | — | |
| SCHEMBL8164803 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL62013 | 0.80 | — | — | |
| SCHEMBL126987 | 0.77 | ALDH1A1 (0.50) | — | |
| SCHEMBL10798531 | 0.76 | CYP3A4 (0.46) | — | |
| SCHEMBL30839716 | 0.75 | CD44 (0.65) | — | |
| SCHEMBL3462069 | 0.75 | CD44 (0.65) | — | |
| SCHEMBL686929 | 0.75 | — | — | |
| SCHEMBL29661770 | 0.75 | — | — | |
| SCHEMBL16497559 | 0.72 | CD44 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707773-A | Preparation method and application of maleimide structure-containing compound | 中国农业大学 | 2025-03-28 | — | — | CN | claimed |
| CN-118373783-A | Method for preparing topramezone intermediate dihydro-isoxazole compound | 帕潘纳(北京)科技有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-113214041-A | Novel method for preparing 3-iodine-2 bromotoluene | 河北唯达生物医药产业技术研究有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-112876411-A | Compound and application thereof in synthesis of PDL1 antagonist drug molecules | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-103041855-B | Preparation method of catalysts for dichloro-pyridine oxynitride | SHANGHAI NOVEL CHEMICAL TECHNOLOGY CO LTD | 2014-09-10 | — | — | CN | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042791-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3915996-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4580621-A2 | T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS | The Broad Institute, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12344586-B2 | Process for the preparation of biphenylamines | ADAMA MAKHTESHIM LTD. (IL) | 2025-07-01 | — | — | US | disclosed |
| CN-120091815-A | T-type voltage-gated calcium channel enhancer | 广泛研究所股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-5635528-A | RECEPTOR BINDING MODULATORS, FOR CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| CN-1148340-A | Treatment of 5HTZBMethods of receptor-related disorders | LILLY CO ELI (US) | 1997-04-23 | — | — | CN | disclosed |
| EP-0749313-A1 | METHOD FOR TREATING 5HT 2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5508284-A | TREATING 5-HYDROXYTRYPTAMINE MODULATION | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5500431-A | ANTISEROTONINE AGENTS; SEXUAL AND EATING DISORDERS | ELI LILLY AND COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |